Literature DB >> 33770291

Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.

Andrew W Hahn1, Jad Chahoud2, Matthew T Campbell3, Daniel D Karp4, Jennifer Wang1, Bettzy Stephen4, Shi-Ming Tu3, Curtis A Pettaway5, Aung Naing6.   

Abstract

BACKGROUND: Treatment options for unresectable, locally advanced or metastatic penile squamous cell carcinoma (SCC) are limited. Previous studies have shown that 40-62% of patients with penile SCC express PD-L1. We report three cases of locally advanced or metastatic penile SCC treated with pembrolizumab. CASE PRESENTATIONS: Herein, we present three patients with recurrent, locally advanced or metastatic penile SCC who progressed on a platinum-based chemotherapy triplet and were treated with pembrolizumab, administered as part of a phase II clinical trial for rare tumors (NCT02721732). One patient with a microsatellite instability high (MSI-H) tumor experienced a durable partial response to pembrolizumab, underwent surgical consolidation, and remains disease-free 38.7 months later. Two patients experienced progressive disease within 3 months of beginning pembrolizumab. No one experienced a grade 3 or worse treatment-related adverse event.
CONCLUSION: In sum, single-agent pembrolizumab was well tolerated as salvage therapy in a small cohort of patients with unresectable, locally advanced or metastatic penile SCC. Pembrolizumab produced an objective response in an MSI-H tumor, yet it did not control disease in two patients with MSS penile SCC. Rationale combination therapies, including pembrolizumab, warrant further investigation. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02721732 . Registered March 23, 2016.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Locally advanced; MSI-high; Pembrolizumab; Penile squamous cell carcinoma

Mesh:

Substances:

Year:  2021        PMID: 33770291     DOI: 10.1007/s10637-021-01100-x

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  1 in total

1.  Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era.

Authors:  Gavin Hui; Sanaz N Ghafouri; John Shen; Sandy Liu; Alexandra Drakaki
Journal:  Case Rep Oncol Med       Date:  2019-03-25
  1 in total
  7 in total

Review 1.  Emerging Therapies in Penile Cancer.

Authors:  Antonio Machado Alencar; Guru Sonpavde
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

2.  Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers.

Authors:  Karina Cereceda; Nicolas Bravo; Roddy Jorquera; Roxana González-Stegmaier; Franz Villarroel-Espíndola
Journal:  Cancers (Basel)       Date:  2022-06-06       Impact factor: 6.575

3.  Efficacy of Applying Kanglaite Injection under Incentive Nursing Intervention in Treating Patients with Advanced Penile Carcinoma and Its Effect on Treatment Compliance.

Authors:  Juan Wang; Qingyan Liu; Mei Hong; Ge Li; Yong Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-25       Impact factor: 2.629

Review 4.  Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis.

Authors:  Tynisha S Rafael; Jossie Rotman; Oscar R Brouwer; Henk G van der Poel; Constantijne H Mom; Gemma G Kenter; Tanja D de Gruijl; Ekaterina S Jordanova
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

5.  Pembrolizumab as a promising intervention for advanced penile cancer.

Authors:  Daniela Vinueza-Obando; Philippe E Spiess; Herney Andrés García-Perdomo
Journal:  Int Braz J Urol       Date:  2022 Jul-Aug       Impact factor: 3.050

Review 6.  An update on treatment of penile cancer.

Authors:  Juskaran Chadha; Jad Chahoud; Philippe E Spiess
Journal:  Ther Adv Med Oncol       Date:  2022-09-24       Impact factor: 5.485

7.  Immune checkpoint inhibitors in penile cancer.

Authors:  Carlo Buonerba; Luca Scafuri; Ferdinando Costabile; Bruno D'Ambrosio; Simona Gatani; Pasquale Verolino; Rossella Di Trolio; Vincenzo Cosimato; Antonio Verde; Giuseppe Di Lorenzo
Journal:  Future Sci OA       Date:  2021-05-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.